Agenus Inc. sell StockNews.com
Start price
16.03.24
/
50%
€0.54
Target price
16.03.25
-
Performance (%)
-23.40%
Price
11.04.24
€0.41
Summary
This prediction is currently active. The price of Agenus Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -23.40%. This prediction currently runs until 16.03.25. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionAgenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Agenus Inc. | - | - |
| iShares Core DAX® | -0.922% | -1.993% |
| iShares Nasdaq 100 | 0.371% | -0.868% |
| iShares Nikkei 225® | 2.224% | -5.187% |
| iShares S&P 500 | -0.026% | -0.918% |
Comments by StockNews_com for this prediction
In the thread Agenus Inc. diskutieren
Agenus Inc. (NASDAQ: AGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for AGEN provided by MarketBeat